Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (52) 52
male (40) 40
female (38) 38
middle aged (37) 37
aged (36) 36
adult (32) 32
hematology (32) 32
index medicus (21) 21
aged, 80 and over (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
oncology (11) 11
prognosis (11) 11
disease-free survival (10) 10
treatment outcome (10) 10
multiple myeloma (9) 9
adolescent (8) 8
leukemia (8) 8
multiple myeloma - drug therapy (8) 8
multiple myeloma - mortality (8) 8
survival (8) 8
survival rate (8) 8
follow-up studies (7) 7
transplantation (7) 7
chemotherapy (6) 6
prospective studies (6) 6
recurrence (6) 6
retrospective studies (6) 6
risk factors (6) 6
survival analysis (6) 6
thalidomide (6) 6
thalidomide - administration & dosage (6) 6
transplantation, autologous (6) 6
immunology (5) 5
lymphoma, non-hodgkin - drug therapy (5) 5
lymphoma, non-hodgkin - pathology (5) 5
multiple myeloma - pathology (5) 5
remission induction (5) 5
abridged index medicus (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
cancer (4) 4
care and treatment (4) 4
child (4) 4
chronic lymphocytic leukemia (4) 4
combined modality therapy (4) 4
cyclophosphamide (4) 4
dexamethasone - administration & dosage (4) 4
disease (4) 4
expression (4) 4
fludarabine (4) 4
italy - epidemiology (4) 4
leukemia, lymphocytic, chronic, b-cell - blood (4) 4
leukemia, lymphocytic, chronic, b-cell - genetics (4) 4
lymphoma, non-hodgkin - therapy (4) 4
mortality (4) 4
multiple myeloma - blood (4) 4
multiple myeloma - therapy (4) 4
neoplasm staging (4) 4
pegylated liposomal doxorubicin (4) 4
polymerase chain reaction (4) 4
soluble interleukin-2 receptor (4) 4
stem cells (4) 4
therapy (4) 4
time factors (4) 4
age factors (3) 3
b-cell lymphoma (3) 3
chromosome aberrations (3) 3
chronic lymphocytic-leukemia (3) 3
colony-stimulating factor (3) 3
complications and side effects (3) 3
dexamethasone (3) 3
diagnosis (3) 3
doxorubicin - administration & dosage (3) 3
doxorubicin - analogs & derivatives (3) 3
flow cytometry (3) 3
further section (3) 3
genetic aspects (3) 3
guidelines (3) 3
hematology, oncology and palliative medicine (3) 3
hematopoietic stem cell transplantation (3) 3
incidence (3) 3
interleukin-10 (3) 3
interleukin‐10 (3) 3
leukemia, lymphocytic, chronic, b-cell - enzymology (3) 3
leukemia, lymphocytic, chronic, b-cell - pathology (3) 3
lymphoma (3) 3
lymphoma, non-hodgkin - blood (3) 3
lymphoma, non-hodgkin - immunology (3) 3
melphalan - administration & dosage (3) 3
melphalan - therapeutic use (3) 3
microbiology (3) 3
mutation (3) 3
non-hodgkin's lymphoma (3) 3
non-hodgkins lymphoma (3) 3
non‐hodgkin's lymphoma (3) 3
original paper (3) 3
pathology (3) 3
prognostic-factors (3) 3
risk (3) 3
soluble interleukin‐2 receptor (3) 3
trial (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia after Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey
by Girmenia, Corrado and Bertaina, Alice and Piciocchi, Alfonso and Perruccio, Katia and Algarotti, Alessandra and Busca, Alessandro and Cattaneo, Chiara and Raiola, Anna Maria and Guidi, Stefano and Iori, Anna Paola and Candoni, Anna and Irrera, Giuseppe and Milone, Giuseppe and Marcacci, Giampaolo and Scimè, Rosanna and Musso, Maurizio and Cudillo, Laura and Sica, Simona and Castagna, Luca and Corradini, Paolo and Marchesi, Francesco and Pastore, Domenico and Alessandrino, Emilio Paolo and Annaloro, Claudio and Ciceri, Fabio and Santarone, Stella and Nassi, Luca and Farina, Claudio and Viscoli, Claudio and Rossolini, Gian Maria and Bonifazi, Francesca and Rambaldi, Alessandro and Capria, Saveria and Bertaina, A and Mastronuzzi, Angela and Pagliara, Daria and Bernaschi, Paola and Amico, Lucia and Carotti, Alessandra and Mencacci, Antonella and Busca, A and Bruno, Benedetto and Costa, Cristina and Passi, Angela and Ravizzola, Giuseppe and Angelucci, Emanuele and Marchese, Anna and Pecile, Patrizia and Candoni, A and Ventura, Giovanna and Fanin, Renato and Scarparo, Claudio and Barbaro, Angelo and Leotta, Salvatore and Marchese, Anna Elisa and Marcacci, G and Becchimanzi, Cristina and Donnarumma, Daniela and Tringali, Stefania and Baldi, Maria Teresa and Scalone, Renato and Cudillo, L and Picardi, Alessandra and Arcese, William and Fontana, Carla and Sica, S and Giammarco, Sabrina and Spanu, Teresa and Castagna, L and Crocchiolo, Roberto and Casari, Erminia and Mussetti, Alberto and Conte, Eutilia and Ensoli, Fabrizio and Miragliotta, Giuseppe and Marone, Piero and Arghittu, Milena and Greco, Raffaella and Forcina, Alessandra and Chichero, Paola and Santarone, S and Di Bartolomeo, Paolo and Fazii, Paolo and Kroumova, Vesselina and Decembrino, Nunzia and Zecca, Marco and Pisapia, Giovanni and Palazzo, Giulia and Lanino, Edoardo and Faraci, Maura and Castagnola, Elio and Bandettini, Roberto and Pastano, Rocco and Sammassimo, Simona and Passerini, Rita and Stefani, Piero Maria and Gherlinzoni, Filippo and Rigoli, Roberto and Prezioso, Lucia and Cambò, Benedetta and ... and GITMO and AMCLI and Gruppo Italiano Trapianto di Midollo Osseo (GITMO) and Associazione Microbiologi Clinici Italiani (AMCLI)
Clinical Infectious Diseases, ISSN 1058-4838, 12/2017, Volume 65, Issue 11, pp. 1884 - 1896
In a prospective study in allogeneic and autologous hematopoietic stem cell transplants the probability of pre-engraftment Gram-negative bacteremia was 17.3%... 
epidemiology | multidrug resistance | stem cell transplant | Gram negative bacteremia | survival | MORTALITY | INFECTIOUS DISEASES | BACTERIAL-INFECTIONS | GUIDELINES | RESISTANT KLEBSIELLA-PNEUMONIAE | MICROBIOLOGY | NEUTROPENIC PATIENTS | IMMUNOLOGY | RECIPIENTS | ANTIMICROBIAL RESISTANCE | 4TH EUROPEAN CONFERENCE | BLOOD-STREAM INFECTIONS | Prospective Studies | Age Factors | Humans | Middle Aged | Child, Preschool | Bacteremia - mortality | Infant | Male | Transplantation, Autologous | Gram-Negative Bacteria - isolation & purification | Transplantation, Homologous | Incidence | Bacteremia - microbiology | Young Adult | Drug Resistance, Multiple, Bacterial | Hematopoietic Stem Cell Transplantation - adverse effects | Bacteremia - etiology | Adult | Female | Transplantation Conditioning - adverse effects | Child | Risk Factors | Gram-Negative Bacterial Infections - drug therapy | Escherichia coli - isolation & purification | Adolescent | Gram-Negative Bacterial Infections - epidemiology | Bacteremia - epidemiology | Italy - epidemiology | Aged | Complications and side effects | Usage | Transplantation | Research | Epidemiology | Bacteremia | Risk factors | Hematopoietic stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Array CGH analysis reveals deletion of chromosome 22q11 in CLL with normal karyotype and no fish alterations
by Mestichelli, Francesca and Dalsass, Alessia and Ferretti, Silvia and Camaioni, Elisa and Angelini, Mario and Mei, Sabrina and Pezzoni, Valerio and Travaglini, Fosco and Troiani, Emanuela and Angelini, Stefano and Galieni, Piero
British Journal of Haematology, ISSN 0007-1048, 10/2018, Volume 183, Issue 1, pp. 152 - 155
array CGH | loss of 22q11 | chronic lymphocytic leukaemia | PRAME GENE | CHRONIC LYMPHOCYTIC-LEUKEMIA | COMPARATIVE GENOMIC HYBRIDIZATION | ABERRATIONS | HEMATOLOGY | CYTOGENETICS | EXPRESSION | Chromosome Deletion | Humans | Middle Aged | In Situ Hybridization, Fluorescence | Male | Comparative Genomic Hybridization - methods | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - classification | Chromosome Aberrations | Aged, 80 and over | Female | Aged | Chromosomes, Human, Pair 22 | Karyotype | Cytogenetics | Genetic research | Chromosomes | Analysis | Leukemia | Deletion | Chromosome 22 | Chronic lymphatic leukemia | Chromosome deletion | Clonal deletion
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma
by Mauro, Francesca Romana and Galieni, Piero and Tedeschi, Alessandra and Laurenti, Luca and Del Poeta, Giovanni and Reda, Gianluigi and Motta, Marina and Gozzetti, Alessandro and Murru, Roberta and Caputo, Maria Denise and Campanelli, Melissa and Frustaci, Anna Maria and Innocenti, Idanna and Raponi, Sara and Guarini, Anna and Morabito, Fortunato and Foà, Robin and Gentile, Massimo
American Journal of Hematology, ISSN 0361-8609, 06/2017, Volume 92, Issue 6, pp. 529 - 535
We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who... 
B-CELL LYMPHOMA | WORKING-GROUP | CLL | RISK-FACTORS | PROGNOSTIC-FACTORS | MODERN-ERA | DISEASE | RETROSPECTIVE ANALYSIS | HEMATOLOGY | EPSTEIN-BARR-VIRUS | STERNBERG CELLS | Doxorubicin - therapeutic use | Prognosis | Dacarbazine - therapeutic use | Humans | Middle Aged | Male | Neoplasms, Second Primary - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Vinblastine - therapeutic use | Hodgkin Disease - etiology | Bleomycin - therapeutic use | Aged, 80 and over | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Retrospective Studies | Risk Factors | Hodgkin Disease - diagnosis | Treatment Outcome | Combined Modality Therapy - adverse effects | Remission Induction | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Neoplasms, Second Primary - diagnosis | Neoplasms, Second Primary - etiology | Leukemia, Lymphocytic, Chronic, B-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Combined Modality Therapy - methods | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Mutation | Neoplasms, Second Primary - drug therapy | Immunoglobulin Heavy Chains - genetics | Medicine, Experimental | Medical research | Chronic lymphocytic leukemia | Lymphomas | Patient outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Once Weekly Versus Twice Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies
by Bringhen, Sara and Mina, Roberto and Petrucci, Maria Teresa and De Paoli, Lorenzo and Ballanti, Stelvio and Musto, Pellegrino and Offidani, Massimo and Spada, Stefano and Benevolo, Giulia and Ponticelli, Elena and Galieni, Piero and Cavo, Michele and Caravita di Toritto, Tommaso and Conticello, Concetta and Montefusco, Vittorio and Palumbo, Antonio and Boccadoro, Mario and Larocca, Alessandra
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1990 - 1990
Abstract INTRODUCTION: Twice weekly carfilzomib is approved at two different doses, 27 mg/m2 in combination with lenalidomide and dexamethasone, and 56 mg/m2... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies
by Mina, Roberto and Larocca, Alessandra and Petrucci, Maria Teresa and Gaidano, Gianluca and Ballanti, Stelvio and Musto, Pellegrino and Offidani, Massimo and Omedé, Paola and Benevolo, Giulia and Malfitano, Alessandra and Galieni, Piero and Cavo, Michele and Caravita di Toritto, Tommaso and Del Fabro, Vittorio and Montefusco, Vittorio and Palumbo, Antonio and Boccadoro, Mario and Bringhen, Sara
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3240 - 3240
Abstract INTRODUCTION: High-risk cytogenetic abnormalities, such as del(17p), t(4;14), and/or t(14;16), are associated to an unfavorable prognosis. Several... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: A randomized study
by Balduini, Carlo L and Gugliotta, Luigi and Luppi, Mario and Laurenti, Luca and Klersy, Catherine and Pieresca, Carla and Quintini, Gerlando and Iuliano, Francesco and Re, Rossana and Spedini, Pierangelo and Vianelli, Nicola and Zaccaria, Alfonso and Pogliani, Enrico Maria and Musso, Roberto and Bobbio Pallavicini, Enrico and Quarta, Giovanni and Galieni, Piero and Fragasso, Alberto and Casella, Gianluca and Noris, Patrizia and Ascari, Edoardo and Italian TTP Study Grp and Italian TTP Study Group and The Italian TTP Study Group
Annals of Hematology, ISSN 0939-5555, 06/2010, Volume 89, Issue 6, pp. 591 - 596
Therapeutic plasma exchange (PE) is the accepted therapy for thrombotic thrombocytopenic purpura (TTP). Because not all patients achieve remission, other... 
Thrombocytopenia | Plasma exchange | TTP | Steroids | HEMOLYTIC-UREMIC SYNDROME | ANTI-ADAMTS13 ANTIBODIES | CLEAVING PROTEASE | PROGNOSTIC VALUE | TRIAL | PLASMA-EXCHANGE | ADAMTS13 ACTIVITY | CRYOSUPERNATANT | HEMATOLOGY | CYCLOSPORINE | REMISSION | Humans | Middle Aged | Male | Treatment Outcome | Purpura, Thrombocytopenic, Idiopathic - mortality | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Dose-Response Relationship, Drug | Acute-Phase Reaction - drug therapy | Purpura, Thrombocytopenic, Idiopathic - immunology | Survival Analysis | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Acute-Phase Reaction - mortality | Methylprednisolone - administration & dosage | Thrombocytopenic purpura | Corticosteroids | Clinical trials | Respiratory tract diseases | Dosage and administration | Methylprednisolone | Standards
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
by Visani, Giuseppe and Malerba, Lara and Stefani, Pietro Maria and Capria, Saveria and Galieni, Piero and Gaudio, Francesco and Specchia, Giorgina and Meloni, Giovanna and Gherlinzoni, Filippo and Giardini, Claudio and Falcioni, Sadia and Cuberli, Francesca and Gobbi, Marco and Sarina, Barbara and Santoro, Armando and Ferrara, Felicetto and Rocchi, Marco and Ocio, Enrique M and Caballero, Maria Dolores and Isidori, Alessandro
Blood, ISSN 0006-4971, 09/2011, Volume 118, Issue 12, pp. 3419 - 3425
We designed a phase 1-2 study to evaluate the safety and the efficacy of increasing doses of bendamustine (160 mg/m(2), 180 mg/m2, and 200 mg/m2 given on days... 
EVERY 3 WEEKS | CONVENTIONAL CHEMOTHERAPY | B-CELL | SOLID TUMORS | BONE-MARROW-TRANSPLANTATION | REGIMEN-RELATED TOXICITY | NON-HODGKINS-LYMPHOMA | COMBINATION CHEMOTHERAPY | HIGH-DOSE CHEMOTHERAPY | PHASE-II MULTICENTER | HEMATOLOGY | Lymphoma, Non-Hodgkin - immunology | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Cytarabine - therapeutic use | Hodgkin Disease - pathology | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Transplantation, Autologous | Melphalan - therapeutic use | Lymphoma, Non-Hodgkin - pathology | Nitrogen Mustard Compounds - therapeutic use | Adult | Female | Transplantation Conditioning - methods | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Etoposide - therapeutic use | Graft Survival | Remission Induction | Cytarabine - administration & dosage | Melphalan - administration & dosage | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Non-Hodgkin - therapy | Hodgkin Disease - therapy | Hodgkin Disease - immunology | Aged | Salvage Therapy - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: Correlations with clinicobiologic parameters
by Rigolin, Gian Matteo and Cibien, Francesca and Martinelli, Sara and Formigaro, Luca and Rizzotto, Lara and Tammiso, Elisa and Saccenti, Elena and Bardi, Antonella and Cavazzini, Francesco and Ciccone, Maria and Nichele, Ilaria and Pizzolo, Giovanni and Zaja, Francesco and Fanin, Renato and Galieni, Piero and Dalsass, Alessia and Mestichelli, Francesca and Testa, Nicoletta and Negrini, Massimo and Cuneo, Antonio
Blood, ISSN 0006-4971, 03/2012, Volume 119, Issue 10, pp. 2310 - 2313
It is unclear whether karyotype aberrations that occur in regions uncovered by the standard fluorescence in situ hybridization (FISH) panel have prognostic... 
Prognosis | Mitogens - pharmacology | Humans | Middle Aged | Male | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Metaphase - drug effects | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Karyotyping - methods | Metaphase - genetics | Oligonucleotides - pharmacology | Chromosome Aberrations | Survival Analysis | Aged, 80 and over | Interleukin-2 - pharmacology | Adult | Female | Aged | In Situ Hybridization, Fluorescence - methods | Karyotype | Cohort Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
by Bringhen, S and Mina, R and Petrucci, MT and Gaidano, G and Ballanti, S and Musto, P and Offidani, M and Spada, S and Benevolo, G and Ponticelli, E and Galieni, P and Cavo, M and Di Toritto, TC and Di Raimondo, F and Montefusco, V and Palumbo, A and Boccadoro, M and Larocca, A
HAEMATOLOGICA, ISSN 0390-6078, 07/2019, Volume 104, Issue 8, pp. 1640 - 1647
Twice-weekly carfilzomib is approved at 27 and 56 mg/m(2) to treat relapsed multiple myeloma patients. In the phase III study ARROW, once-weekly 70 mg/m(2)... 
SURVIVAL | MULTICENTER | PHASE 1/2 | CYCLOPHOSPHAMIDE | LENALIDOMIDE | RISK | OPEN-LABEL | BORTEZOMIB | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study
by Rosti, Giovanni and Petrini, Mario and Bosi, Alberto and Galieni, Piero and Bernardi, Daniele and Giglio, Gianfranco and Dorotea, Laura and Falini, Brunangelo and Scelzi, Elvira and Veltri, Enzo and Castelli, Roberto and Longagnani, Chiara and Raggi, Tommaso and Simonetti, Federico
Therapeutic Advances in Medical Oncology, ISSN 1758-8340, 1/2017, Volume 9, Issue 1, pp. 22 - 32
Background: Many patients with solid tumours or nonmyeloid haematopoietic tumours develop symptomatic anaemia, which has a major impact on quality of life... 
epoetin alfa | erythropoiesis-stimulating agents | biosimilar | chemotherapy-induced anaemia | erythropoietin | HEMOGLOBIN | CHEMOTHERAPY-INDUCED ANEMIA | SAFETY | GUIDELINES | PATTERNS | CANCER-TREATMENT ACT | EUROPE | ONCOLOGY | OUTCOMES | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)
by Gay, Francesca and Cerrato, Chiara and Rota Scalabrini, Delia and Galli, Monica and Belotti, Angelo and Zamagni, Elena and Ledda, Antonio and Grasso, Mariella and Angelucci, Emanuele and Liberati, Anna Marina and Tosi, Patrizia and Pisani, Francesco and Spada, Stefano and Annibali, Ombretta and Baraldi, Anna and Omedé, Paola and Galieni, Piero and Rizzi, Rita and Pescosta, Norbert and Ronconi, Sonia and Vincelli, Donatella and Cafro, Anna Maria and Offidani, Massimo and Palumbo, Antonio and Musto, Pellegrino and Cavo, Michele and Boccadoro, Mario
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 121 - 121
Abstract Background: Proteasome inhibitor (PI)-based induction and consolidation proved to be effective in newly diagnosed multiple myeloma (NDMM) patients... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Outcome of Soft-Tissue Plasmocytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs
by Montefusco, Vittorio and Gay, Francesca and Spada, Stefano and De Paoli, Lorenzo and Di Raimondo, Francesco and Ribolla, Rossella and Musolino, Caterina and Patriarca, Francesca and Musto, Pellegrino and Galieni, Piero and Cavo, Michele and Ballanti, Stelvio and Nozzoli, Chiara and Cascavilla, Nicola and Ben-Yehuda, Dina and Nagler, Arnon and Hajek, Roman and Offidani, Massimo and Liberati, Anna Marina and Corradini, Paolo and Boccadoro, Mario
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3235 - 3235
Abstract Introduction Multiple myeloma (MM) can be associated with paraskeletal (PP) or extramedullary (EMP) plasmocytomas (PL). Although PLs are relatively... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma
by Visani, Giuseppe and Stefani, Pietro Maria and Capria, Saveria and Malerba, Lara and Galieni, Piero and Gaudio, Francesco and Specchia, Giorgina and Meloni, Giovanna and Gherlinzoni, Filippo and Gonella, Roberta and Gobbi, Marco and Santoro, Armando and Ferrara, Felicetto and Rocchi, Marco and Ocio, Enrique M and Caballero, Maria Dolores and Loscocco, Federica and Isidori, Alessandro
Blood, ISSN 0006-4971, 11/2014, Volume 124, Issue 19, pp. 3029 - 3031
HODGKINS-LYMPHOMA | THERAPY | HEMATOLOGY | RITUXIMAB | TRANSPLANTATION | Cytarabine - therapeutic use | Humans | Drug Resistance, Neoplasm | Transplantation, Autologous | Combined Modality Therapy | Melphalan - therapeutic use | Antineoplastic Agents, Alkylating - therapeutic use | Antimetabolites, Antineoplastic - therapeutic use | Bendamustine Hydrochloride | Nitrogen Mustard Compounds - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hematopoietic Stem Cell Transplantation - methods | Lymphoma, Non-Hodgkin - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: Analysis of 75 patients
by Zinzani, Pier Luigi and Magagnoli, Massimo and Galieni, Piero and Martelli, Maurizio and Poletti, Venerino and Zaja, Francesco and Molica, Stefano and Zaccaria, Alfonso and Cantonetti, Anna Maria and Gentilini, Patrizia and Guardigni, Luciano and Gherlinzoni, Filippo and Ribersani, Michela and Bendandi, Maurizio and Albertini, Patrizia and Tura, Sante
Journal of Clinical Oncology, ISSN 0732-183X, 04/1999, Volume 17, Issue 4, pp. 1254 - 1258
Purpose: Nongastrointestinal locations represent about 30% to 40% of all low-grade mucosa-associated lymphoid tissue (MALT) lymphomas. We report a... 
B-CELL LYMPHOMA | HEPATITIS-C VIRUS | NEOPLASMS | ONCOLOGY | NON-HODGKINS-LYMPHOMAS | MYOEPITHELIAL SIALADENITIS | CONJUNCTIVA | SALIVARY-GLANDS | HELICOBACTER-PYLORI | GASTRIC LYMPHOMA | MALT LYMPHOMA | Prognosis | Humans | Middle Aged | Interferon-alpha - therapeutic use | Lymphoma, B-Cell, Marginal Zone - therapy | Male | Survival Rate | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Lymphoma, B-Cell, Marginal Zone - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies
Journal Article
Details down arrow
15. Full Text Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard‐risk cytogenetics
by Vagnoni, Davide and Travaglini, Fosco and Pezzoni, Valerio and Ruggieri, Miriana and Bigazzi, Catia and Dalsass, Alessia and Mestichelli, Francesca and Troiani, Emanuela and Falcioni, Sadia and Mazzotta, Serena and Natale, Annalisa and Angelini, Mario and Ferretti, Silvia and Angelini, Stefano and Galieni, Piero
British Journal of Haematology, ISSN 0007-1048, 08/2015, Volume 170, Issue 4, pp. 523 - 531
Summary Detection of circulating plasma cells (PCs) in multiple myeloma (MM) patients is a well‐known prognostic factor. We evaluated circulating PCs by flow... 
multiple myeloma | flow cytometry | cytogenetic‐risk | prognostic factors | circulating plasma cells | Flow cytometry | Cytogenetic-risk | Circulating plasma cells | Prognostic factors | Multiple myeloma | SURVIVAL | PREDICTOR | QUANTIFICATION | BONE-MARROW | DISORDERS | PERIPHERAL-BLOOD | TRANSPLANTATION | cytogenetic-risk | FLOW-CYTOMETRY | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | STRATIFICATION | Multiple Myeloma - diagnosis | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Survival Rate | Plasma Cells - pathology | Biomarkers, Tumor - blood | Disease-Free Survival | Multiple Myeloma - pathology | Multiple Myeloma - therapy | Aged, 80 and over | Cytogenetics | Female | Plasma Cells - metabolism | Aged | Multiple Myeloma - blood | Care and treatment | Genetic aspects | Prognosis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Circulating Plasma Cells in Newly Diagnosed Symptomatic Multiple Myeloma As a Prognostic Marker for Patients with Standard-Risk Cytogenetics
by Vagnoni, Davide and Travaglini, Fosco and Angelini, Stefano and Dalsass, Alessia and Mestichelli, Francesca and Angelini, Mario and Pezzoni, Valerio and Natale, Annalisa and Ruggieri, Miriana and Bigazzi, Catia and Troiani, Emanuela and Falcioni, Sadia and Mazzotta, Serena and Galieni, Piero
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 3353 - 3353
Abstract Multiple Myeloma (MM) is a clonal B-cell disorder characterized by accumulation of malignant plasma cells (PCs) in the bone marrow (BM). Circulating... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study
by Bringhen, Sara and Rossi, Davide and Larocca, Alessandra and Corradini, Paolo and Galieni, Piero and Malfitano, Alessandra and Aschero, Simona and Offidani, Massimo and Liberati, Anna Marina and Genuardi, Mariella and Gaidano, Gianluca and Palladino, Carmela and Gentilini, Fabiana and Boccadoro, Mario and Sonneveld, Pieter and Palumbo, Antonio
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 1828 - 1828
Abstract Background Carfilzomib is a novel second generation proteasome-inhibitor with significant anti-MM activity and favorable toxicity profile. In a recent... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma
: MAURO et al
by Mauro, Francesca Romana and Galieni, Piero and Tedeschi, Alessandra and Laurenti, Luca and Del Poeta, Giovanni and Reda, Gianluigi and Motta, Marina and Gozzetti, Alessandro and Murru, Roberta and Caputo, Maria Denise and Campanelli, Melissa and Frustaci, Anna Maria and Innocenti, Idanna and Raponi, Sara and Guarini, Anna and Morabito, Fortunato and Foà, Robin and Gentile, Massimo
American Journal of Hematology, ISSN 0361-8609, 06/2017, Volume 92, Issue 6, pp. 529 - 535
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights